Brasília – A new wave of patent expirations for high-cost biologic medicines is set to significantly alter Brazil’s pharmaceutical landscape over the next decade. According to industry specialists, at least 15 major biologics—including treatments for cancer, autoimmune diseases and rare conditions—will lose exclusivity by 2035, opening space for biosimilars and intensifying competition in the domestic market. The shift is expected to expand patient access, reduce budget pressures on both the public and private health sectors, and stimulate local production capabilities.

Experts interviewed by Futuro da Saúde note that Brazil still faces regulatory, technological and industrial challenges to fully benefit from this transition. Manufacturing complexity, limited biotechnological infrastructure and dependence on imported inputs may constrain the speed at which biosimilars reach the market. Policymakers and industry leaders argue that coordinated investment—through public-private partnerships, innovation incentives and regulatory streamlining—will be essential to strengthen Brazil’s position in the global biologics and biosimilars arena.

Source: Futuro da Saúde